- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04813328
The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms
A Pilot Study of the Effects of Helminth Infection and SARS-CoV-2 Seropositivity on Immune Response and the Intestinal Microbiota in India
Study Overview
Status
Conditions
Detailed Description
This is a pilot, cross-sectional, sample collection study to characterize the immune response and intestinal microbiota in people with and without SARS-CoV-1 antibodies and helminth infection.
A target sample size of 1500 participants aged 5 years or older will undergo a one-time blood and stool collection for SARS-CoV-2 antibody testing, diagnosis of parasitic infections, and experimental studies including transcriptomics (RNA) and microbiome (intestinal microorganisms) characterization. Participants willing to take part in the study will be selected from households in the Tiruvallur district, Tamil Nadu, India. Individual study participation involves a single study visit. Participants will be informed of the results of clinical testing and will be referred for medical care as appropriate.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Tamilnadu
-
Chennai, Tamilnadu, India
- Recruiting
- National Institute for Research in Tuberculosis - International Centers for Excellence in Research (NIRT-ICER)
-
Contact:
- Subash Babu, MBBS, PhD
- Phone Number: 044-28369711
- Email: sbabu@icerindia.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to provide informed consent.
Exclusion Criteria:
- Poor venous access precluding venipuncture.
- History of any illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the participant's participation in the protocol, or compromise the scientific objectives.
Participants may be co-enrolled in other studies; however study staff should be notified of co-enrollment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Ecologic or Community
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with helminth infections
Time Frame: Day 1
|
Measured by qPCR diagnostics of stool DNA extraction
|
Day 1
|
Number of participants with SARS-CoV-2 antibodies
Time Frame: Day 1
|
Measured by real-time qPCR (quantitative polymerase chain reaction) assay
|
Day 1
|
Number of participants with positive malaria test
Time Frame: Day 1
|
Measured by fingerprick blood samples
|
Day 1
|
Average Differential blood count
Time Frame: Day 1
|
Measured from venipuncture blood samples
|
Day 1
|
Average Hematocrit levels
Time Frame: Day 1
|
Measured from venipuncture blood samples
|
Day 1
|
Number of participants with latent tuberculosis infection
Time Frame: Day 1
|
Measured by IFN-γ release assay
|
Day 1
|
Number of participants with Wuchereria bancrofti infection
Time Frame: Day 1
|
Measured by enzyme-linked immunosorbent assay (ELISA)
|
Day 1
|
Number of participants with Strongyloides stercoralis infection
Time Frame: Day 1
|
Measured by enzyme-linked immunosorbent assay (ELISA)
|
Day 1
|
Number of participants with Ascaris infection
Time Frame: Day 1
|
Stool sample analysis DNA extraction for qPCR and 16S sequencing
|
Day 1
|
Number of participants with hookworm infection
Time Frame: Day 1
|
Stool sample analysis DNA extraction for qPCR and 16S sequencing
|
Day 1
|
Number of participants with Strongyloides infection
Time Frame: Day 1
|
Stool sample analysis using Baermann technique, DNA extraction for qPCR and 16S sequencing
|
Day 1
|
Number of participants with Trichuris infection
Time Frame: Day 1
|
Stool sample analysis using DNA extraction for qPCR and 16S sequencing
|
Day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: P'ng Loke, PhD, National Institutes of Health (NIH)
- Principal Investigator: Subash Babu, MBBS, PhD, National Institute for Research in Tuberculosis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SARS-CoV-2/helminth
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece